Maintenance chemotherapy in non-small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Maintenance chemotherapy in non-small cell lung cancer.
Recent trials have shown a benefit with maintenance therapy after 4 to 6 cycles of chemotherapy. These trials have shown improvement in progression-free survival using agents approved as second-line therapy in non-small cell lung cancer. Trials using erlotinib and pemetrexed showed improvement in overall survival. Consideration of trial design is critical for the interpretation of these results...
متن کاملMaintenance chemotherapy for non-small-cell lung cancer.
Currently, platinum-based combination chemotherapy is the standard first-line chemotherapy for non-small-cell lung cancer (NSCLC). Historically, platinum-based chemotherapy has been recommended for up to six cycles even for responders, and second-line chemotherapy has been considered when disease progression is confirmed. In spite of extensive investigations into maintenance chemotherapy, no po...
متن کاملMaintenance Chemotherapy Use for Advanced Non-Small Cell Lung Cancer in an Australian Cancer Centre
Background To investigate the rates of maintenance therapy in advanced non-small cell cancer, the reasons for not progressing to second line therapy at disease progression at our cancer centre and to use this data as a way to institute it into clinical practice in our cancer centre. Method This study was approved by the ethics committee. The data was collected from a purpose built cancer unit...
متن کاملMaintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report
A 53-years-old woman was diagnosed with lung adenocarcinoma state IV (synchronous pleural involvement) in April 2009. First-line systemic treatment included six cycles of Carboplatin, Paclitaxel, and Bevacizumab. Partial response was achieved. Maintenance therapy with Bevacizumab and Pemetrexed was given from September 2009 to February 2010. No response changes were observed. Immunotherapy was ...
متن کاملMaintenance therapies in advanced non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) has the second highest incidence of any newly diagnosed cancer and also has the highest mortality of any cancer type [1]. The majority of patients present with late-stage disease, by which time systemic therapy (chemotherapy) has become the primary treatment and platinum doublet chemotherapy is the first-line choice among patients with advanced disease (stage ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2006
ISSN: 0923-7534
DOI: 10.1093/annonc/mdj928